Ravulizumab: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Recovery RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−5%

Mortality (2)−5%

RCTs (2)−5%

RCT mortality (2)−5%

Late (2)−5%

00.511.5+

← Ravulizumab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Ravulizumab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Annane (RCT)−8%1.08 · 0.74–1.56death55/13525/66ALXN1210-COV-305Ventilated patients Hall (RCT)1%0.99 · 0.52–1.87death135 (n)145 (n)TACTIC-R

Late treatment−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.76

All studies−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7600.511.52+

Rotate screen for more detailsIncrease width for more details

← Ravulizumab
reduces riskRavulizumab
increases risk →

c19early.org

October 2026

Ravulizumab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Annane (RCT)−8%1.08 · 0.74–1.5655/13525/66ALXN1210-COV-305Ventilated patients Hall (RCT)1%0.99 · 0.52–1.87135 (n)145 (n)TACTIC-R

Late treatment−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.76

All studies−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7600.511.52+

Rotate screen for more detailsIncrease width for more details

← Ravulizumab
reduces riskRavulizumab
increases risk →

c19early.org

October 2026

Ravulizumab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Annane (RCT)−8%1.08 · 0.74–1.56death55/13525/66ALXN1210-COV-305Ventilated patients Hall (RCT)1%0.99 · 0.52–1.87death135 (n)145 (n)TACTIC-R

Late treatment−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.76

All studies−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7600.511.52+

Rotate screen for more detailsIncrease width for more details

← Ravulizumab
reduces riskRavulizumab
increases risk →

c19early.org

October 2026

Ravulizumab COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Hall (RCT)−3%1.03 · 0.76–1.41no disch.135 (n)145 (n)TACTIC-R

Late treatment−3%1.03 · 0.76–1.41135 (n)145 (n)3% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.86

All studies−3%1.03 · 0.76–1.41135 (n)145 (n)3% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8600.511.52+

Rotate screen for more detailsIncrease width for more details

← Ravulizumab
reduces riskRavulizumab
increases risk →

c19early.org

October 2026

Ravulizumab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Annane (RCT)−8%1.08 · 0.74–1.56death55/13525/66ALXN1210-COV-305Ventilated patients Hall (RCT)1%0.99 · 0.52–1.87death135 (n)145 (n)TACTIC-R

Late treatment−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.76

All studies−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7600.511.52+

Rotate screen for more detailsIncrease width for more details

← Ravulizumab
reduces riskRavulizumab
increases risk →

c19early.org

October 2026

Ravulizumab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Annane (RCT)−8%1.08 · 0.74–1.5655/13525/66ALXN1210-COV-305Ventilated patients Hall (RCT)1%0.99 · 0.52–1.87135 (n)145 (n)TACTIC-R

Late treatment−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.76

All studies−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7600.511.52+

Rotate screen for more detailsIncrease width for more details

← Ravulizumab
reduces riskRavulizumab
increases risk →

c19early.org

October 2026

Ravulizumab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Annane (RCT)−8%1.08 · 0.74–1.56death55/13525/66ALXN1210-COV-305Ventilated patients Hall (RCT)1%0.99 · 0.52–1.87death135 (n)145 (n)TACTIC-R

Late treatment−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.76

All studies−5%1.05 · 0.76–1.4555/27025/2115% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7600.511.52+

Rotate screen for more detailsIncrease width for more details

← Ravulizumab
reduces riskRavulizumab
increases risk →

c19early.org

October 2026

Ravulizumab COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Annane (RCT)−8%1.08 · 0.74–1.56death55/13525/66ALXN1210-COV-305Ventilated patients Hall (RCT)1%0.99 · 0.52–1.87death135 (n)145 (n)TACTIC-R Hall (RCT)−75%1.75 · 0.71–4.29death11/1357/145TACTIC-R Hall (RCT)−53%1.53 · 0.88–2.67progression135 (n)145 (n)TACTIC-R Hall (RCT)−24%1.24 · 0.60–2.58oxygen135 (n)145 (n)TACTIC-R Hall (RCT)−3%1.03 · 0.76–1.41no disch.135 (n)145 (n)TACTIC-R

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Ravulizumab
reduces riskRavulizumab
increases risk →